Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506348 | 0.83 | KMT2A (0.40) | ALDH1A1MMP12MEN1KMT2AHPGD | |
| SCHEMBL6501062 | 0.83 | TYR (0.45) | ALDH1A1 | |
| SCHEMBL6499914 | 0.82 | CYP4F2 (0.55) | ALDH1A1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL6154419 | 0.82 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL5930158 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TSHRSMN1; SMN2TDP1HTT | |
| SCHEMBL7925112 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2KMT2AHPGD | |
| SCHEMBL6155033 | 0.78 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL6154390 | 0.78 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL6153592 | 0.78 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL6559718 | 0.77 | ALDH1A1 (0.51) | ALDH1A1TSHRSMN1; SMN2TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153684-A1 | PROCESS FOR PREPARATION OF FINGOLIMOD HYDROCHLORIDE | SHIVALIK RASAYAN LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| CN-1290819-C | 2-aminopropane-1,3-glycol compound, its use as medicine and its synthetic intermediate | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2006-12-20 | — | — | CN | disclosed |
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |
| CN-1480450-A | 2-aminopropane-1,3-glycol compound, its use as medicine and its synthetic intermediate | ������ҩ��ʽ���� | 2004-03-10 | — | — | CN | disclosed |
| CN-1137086-C | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | ������ҩ��ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| CN-1259117-A | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153684-A1 | PROCESS FOR PREPARATION OF FINGOLIMOD HYDROCHLORIDE | S1PR2, S1PR4, S1PR5 | ALDH1A1 1249/4885TSHR 2241/4885SMN1; SMN2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.